Incannex Healthcare

Contributing Author

Recent Articles by Incannex Healthcare

Apr-22	Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness IXHL +8.49% GlobeNewswire
Mar-27	Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position IXHL GlobeNewswire
Mar-25	Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research IXHL +15.83% GlobeNewswire
Mar-18	Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development IXHL -6.65% GlobeNewswire
Mar-17	Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement IXHL GlobeNewswire
Mar-12	Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules IXHL -48.41% GlobeNewswire
Mar-12	Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes IXHL -48.41% GlobeNewswire
Feb-25	Incannex Announces Reverse Stock Split IXHL -42.12% GlobeNewswire
Jan-29	Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board IXHL GlobeNewswire
Jan-22	Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program IXHL GlobeNewswire
Jan-15	Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards IXHL GlobeNewswire
Jan-14	Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 IXHL GlobeNewswire
Dec-03	Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) IXHL +12.68% GlobeNewswire
Oct-30	Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus IXHL +17.78% GlobeNewswire
Oct-22	Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement IXHL GlobeNewswire
Aug-26	Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder IXHL GlobeNewswire
Aug-22	Incannex Healthcare Authorizes $20 Million Share Repurchase Program IXHL +28.52% GlobeNewswire
Aug-08	Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea IXHL GlobeNewswire
Jul-31	Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term IXHL -33.52% GlobeNewswire
Jul-30	Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X IXHL -17.76% GlobeNewswire
Jul-25	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo IXHL -35.58% GlobeNewswire
Jun-24	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch IXHL +10.00% GlobeNewswire
Jun-18	Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X IXHL GlobeNewswire
Jun-17	Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy IXHL +5.53% GlobeNewswire
Jun-12	Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution IXHL +14.57% GlobeNewswire
Jun-03	Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program IXHL GlobeNewswire
May-29	Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance IXHL GlobeNewswire
May-28	Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results IXHL -14.78% GlobeNewswire
May-20	Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution IXHL +20.06% GlobeNewswire
May-16	Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants IXHL GlobeNewswire
May-15	Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates IXHL -61.64% GlobeNewswire
May-14	Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) IXHL +720.63% GlobeNewswire

Incannex Healthcare

Recent Articles by Incannex Healthcare

Upgrade your Finviz experience